Detalhe da pesquisa
1.
Early recapture of response with tofacitinib 10 mg twice daily in patients with ulcerative colitis in OCTAVE Open following dose reduction or treatment interruption in OCTAVE Sustain.
J Gastroenterol Hepatol;
39(2): 264-271, 2024 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37953548
2.
JAK selectivity for inflammatory bowel disease treatment: does it clinically matter?
Gut;
68(10): 1893-1899, 2019 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31227590
3.
Loss of Response to Vedolizumab and Ability of Dose Intensification to Restore Response in Patients With Crohn's Disease or Ulcerative Colitis: A Systematic Review and Meta-analysis.
Clin Gastroenterol Hepatol;
17(5): 838-846.e2, 2019 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29935327
4.
Novel therapeutic targets for inflammatory bowel disease.
J Autoimmun;
85: 103-116, 2017 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28711286
5.
Effectiveness and Safety of Tofacitinib in the Management of Ulcerative Colitis: A Brazilian Observational Multicentric Study.
Crohns Colitis 360;
5(1): otac050, 2023 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36777366
6.
Vedolizumab in Mild-to-Moderate Crohn's Disease Patients Naïve to Biological Therapy: A Multicentric Observational Study.
Crohns Colitis 360;
5(4): otad053, 2023 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37859629
7.
SECOND BRAZILIAN CONSENSUS ON THE MANAGEMENT OF ULCERATIVE COLITIS IN ADULTS: A CONSENSUS OF THE BRAZILIAN ORGANIZATION FOR CROHN'S DISEASE AND COLITIS (GEDIIB).
Arq Gastroenterol;
59(suppl 1): 51-84, 2023.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36995889
8.
SECOND BRAZILIAN CONSENSUS ON THE MANAGEMENT OF CROHN'S DISEASE IN ADULTS: A CONSENSUS OF THE BRAZILIAN ORGANIZATION FOR CROHN'S DISEASE AND COLITIS (GEDIIB).
Arq Gastroenterol;
59(suppl 1): 20-50, 2023.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36995888
9.
Endoscopic Surveillance in Inflammatory Bowel Diseases: Selecting a Suitable Technology.
Front Med (Lausanne);
9: 855652, 2022.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35433767
10.
Gastroenteropancreatic Neuroendocrine Neoplasms in Patients with Inflammatory Bowel Disease: An ECCO CONFER Multicentre Case Series.
J Crohns Colitis;
16(6): 940-945, 2022 Jul 14.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34864927
11.
Clinical and Demographic Profile of Inflammatory Bowel Disease Patients in a Reference Center of São Paulo, Brazil.
Clin Exp Gastroenterol;
14: 91-102, 2021.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33762838
12.
'Treat to Target' in Mild to Moderate Ulcerative Colitis: Evidence to Support this Strategy.
Curr Drug Targets;
22(1): 117-125, 2021.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32718289
13.
TL1A: A New Potential Target in the Treatment of Inflammatory Bowel Disease.
Curr Drug Targets;
22(7): 760-769, 2021.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33475057
14.
JAK selectivity: more precision less troubles.
Expert Rev Gastroenterol Hepatol;
14(9): 789-796, 2020 Sep.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32520647
15.
Optimizing biologic therapy in IBD: how essential is therapeutic drug monitoring?
Nat Rev Gastroenterol Hepatol;
17(11): 702-710, 2020 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32879465
16.
Treat to target or 'treat to clear' in inflammatory bowel diseases: one step further?
Expert Rev Gastroenterol Hepatol;
14(9): 807-817, 2020 Sep.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32762582
17.
Histological healing: should it be considered as a new outcome for ulcerative colitis?
Expert Opin Biol Ther;
20(4): 407-412, 2020 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31847610
18.
Is there a role for therapeutic sphingolipids in inflammatory bowel disease?
Expert Rev Gastroenterol Hepatol;
14(1): 47-54, 2020 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31874053
19.
Modulation of sphingosine-1-phosphate in ulcerative colitis.
Expert Opin Biol Ther;
20(4): 413-420, 2020 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32093531
20.
Author Correction: Crohn's disease.
Nat Rev Dis Primers;
6(1): 42, 2020 05 20.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32433463